Skip to main content
SpringerLink
Log in

Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Summary

We present our findings on interpatient transmission, epidemic control measures, and the outcomes of a series of ten critically ill burn patients who were either colonized or infected with carbapenem-resistant Acinetobacter baumannii (CRAB). None of the five infected patients achieved clinical cure, and all experienced relapses. Microbiological failure was observed in 40% of the infected patients. The isolated CRAB strains were found to carry blaOXA−23 and armA resistance genes. Despite the lack of clinical cure, all five infected patients survived and were discharged from the Burn Intensive Care Unit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

Not applicable.

Code Availability

Not applicable.

References

  1. Teng J, Imani S, Zhou A, Zhao Y, Du L, Deng S et al (2023) Combatting resistance: understanding multi-drug resistant pathogens in intensive care units. Biomed Pharmacother Biomedecine Pharmacother 167:115564. https://doi.org/10.1016/j.biopha.2023.115564

    Article  CAS  Google Scholar 

  2. Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL et al (2019) Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis IJID off Publ Int Soc Infect Dis 79:179–184. https://doi.org/10.1016/j.ijid.2018.11.371

    Article  Google Scholar 

  3. Corcione S, Lupia T, De Rosa FG, Host and Microbiota Interaction Study Group (ESGHAMI) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2020) Microbiome in the setting of burn patients: implications for infections and clinical outcomes. Burns Trauma 8:tkaa033. https://doi.org/10.1093/burnst/tkaa033

    Article  PubMed  PubMed Central  Google Scholar 

  4. Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD (2021) Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother 76(6):1379–1391. https://doi.org/10.1093/jac/dkab015

    Article  CAS  PubMed  Google Scholar 

  5. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240. https://doi.org/10.1016/S1473-3099(20)30796-9

    Article  CAS  PubMed  Google Scholar 

  6. Mellon G, Clec’h C, Picard B, Cohen Y, Jauréguy F (2012) Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother 18(6):958–960. https://doi.org/10.1007/s10156-012-0404-9

    Article  PubMed  Google Scholar 

  7. Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A new twist: the combination of Sulbactam/Avibactam enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) isolates. Antibiot (Basel) 10(5):577. https://doi.org/10.3390/antibiotics10050577

    Article  CAS  Google Scholar 

  8. Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP et al (1985) The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 121(2):182–205. https://doi.org/10.1093/oxfordjournals.aje.a113990

    Article  CAS  PubMed  Google Scholar 

  9. Smoke SM, Brophy A, Reveron S, Iovleva A, Kline EG, Marano M et al (2023) Evolution and transmission of Cefiderocol-Resistant Acinetobacter baumannii during an outbreak in the burn Intensive Care Unit. Clin Infect Dis off Publ Infect Dis Soc Am 76(3):e1261–e1265. https://doi.org/10.1093/cid/ciac647

    Article  Google Scholar 

  10. Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J et al (2023) Clinical outcomes and bacterial characteristics of Carbapenem-resistant Acinetobacter Baumannii among patients from different global regions Clin Infect Dis. https://doi.org/10.1093/cid/ciad556

  11. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA et al (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis 28(4):521–547. https://doi.org/10.1016/j.cmi.2021.11.025

    Article  CAS  Google Scholar 

  12. Gill CM, Santini D, Takemura M, Longshaw C, Yamano Y, Echols R et al (2023 Apr) In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. J Antimicrob Chemother. https://doi.org/10.1093/jac/dkad032

  13. Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates. Antibiotics (Basel). May https://doi.org/10.3390/antibiotics10050577

  14. Rodriguez CH, Brune A, Nastro M, Vay C, Famiglietti A (2020 Jul) In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. J Med Microbiol. https://doi.org/10.1099/jmm.0.001211

  15. Tiseo G, Giordano C, Leonildi A, Riccardi N, Galfo V, Limongi F et al (June 2023) Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization. JAC-Antimicrobial Resist 5. https://doi.org/10.1093/jacamr/dlad078

Download references

Acknowledgements

We would like to thank COPAN ESwab for donating the sampling kits.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France

    Emmanuel Dudoignon, Benjamin Deniau, Maité Chaussard, Maxime Coutrot, Lucie Guillemet, Alexandru Cupaciu, Alexandre Pharaboz, Louis Boutin, Mourad Benyamina, Alexandre Mebazaa, Benoit Plaud & François Dépret

  2. University of Paris Cité, Paris, France

    Emmanuel Dudoignon, Francois Caméléna, Benjamin Deniau, Louis Boutin, Marc Chaouat, Maurice Mimoun, Alexandre Mebazaa, Benoit Plaud, Béatrice Berçot & François Dépret

  3. Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 942 Mascot, Lariboisière Hospital, Paris, France

    Emmanuel Dudoignon, Benjamin Deniau, Louis Boutin, Alexandre Mebazaa, Benoit Plaud & François Dépret

  4. INI-CRCT Network, Nancy, France

    Emmanuel Dudoignon, Benjamin Deniau, Alexandre Mebazaa & François Dépret

  5. FHU PROMICE, Paris, France

    Emmanuel Dudoignon, Benjamin Deniau, Alexandre Mebazaa, Benoit Plaud & François Dépret

  6. Department of Bacteriology, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Paris, France

    Francois Caméléna, Manel Merimèche & Béatrice Berçot

  7. INSERM 1137, IAME, Paris, France

    Francois Caméléna, Manel Merimèche & Béatrice Berçot

  8. Infectious Diseases Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France

    Matthieu Lafaurie

  9. Plastic Surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France

    Marc Chaouat & Maurice Mimoun

  10. Infectious Disease Prevention and Control Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France

    Guillaume Mellon

  11. DMU PRISME, Paris, France

    Guillaume Mellon

Authors
  1. Emmanuel Dudoignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francois Caméléna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthieu Lafaurie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benjamin Deniau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maité Chaussard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maxime Coutrot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lucie Guillemet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alexandru Cupaciu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alexandre Pharaboz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Louis Boutin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mourad Benyamina
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Marc Chaouat
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Maurice Mimoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Manel Merimèche
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Alexandre Mebazaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Benoit Plaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Béatrice Berçot
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. François Dépret
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Guillaume Mellon
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ED, FC, FD and GM: Conceptualization, writing of the original draft and final approval of the version.

ML, BD, MC, MC, LG, AC, AP, LB, MB, MC, MM, AM, MM and BB: Writing review and editing.

Corresponding author

Correspondence to Emmanuel Dudoignon.

Ethics declarations

Consent for publication

The authors affirm that research participants provided informed consent.

Conflict of interest

Emmanuel Dudoignon, François Camelena, Matthieu Lafaurie, Benjamin Deniau, Maite Chaussard, Lucie Guillemet, Alexandru Cupaciu, Alexandre Pharaboz, Louis Boutin, Mourad Benyamina, Manel Merimèche, Alexandre Mebazaa, Benoit Plaud, Béatrice Berçot and Guillaume Mellon have no conflicts of interest to declare.

Marc Chaouat and Maurice Mimmoun have no conflicts of interest to declare.

Francois Dépret reports consulting fees Sedana, biocartis and biomerieux and research grant ministry of health.

Ethics approval

Our ethics committee approved the study (IDRCB, IRB00003835; 2013/17NICB).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dudoignon, E., Caméléna, F., Lafaurie, M. et al. Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit. Eur J Clin Microbiol Infect Dis (2024). https://doi.org/10.1007/s10096-024-04840-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10096-024-04840-9

Keywords

Search

Navigation